title: Elevated expression of astrocyte elevated gene-1 (AEG-1) is correlated with cisplatin-based chemoresistance and shortened outcome in patients with stages III-IV serous ovarian carcinoma.
abstract: OBJECTIVE
  To correlate astrocyte elevated gene-1 (AEG-1) expression with the clinicopathological features and outcome of patients with stages III-IV ovarian serous carcinoma, and to clinically assess the involvement of AEG-1 in acquired cisplatin resistance.
  
  
  RESULTS
  The frequency and intensity of immunohistochemical AEG-1 expression increased in a step-wise fashion from normal to chemosensitive to chemoresistant tissues. These observations were confirmed by Western blot analysis. AEG-1 expression level was correlated with lymph nodal metastasis, histological differentiation, residual tumour size and response to primary chemotherapy. Five-year progression-free survival (PFS) and overall survival (OS) rates were lower in the high-expression group than that in the low-expression group. AEG-1 overexpression was an independent but poor prognostic factor in the OS and PFS of these patients, as determined by multivariate Cox regression analysis. Multivariate logistic regression analysis revealed that the presence of cisplatin-based chemoresistance was significantly associated with expression level of AEG-1 and the degree of residual disease (P = 0.0001 and P = 0.0027, respectively).
  
  
  CONCLUSIONS
  Our findings indicate that tumour AEG-1 overexpression is associated with poor prognosis and cisplatin resistance in advanced serous ovarian cancer.
authors.affiliation: Department of Pathology, The Third Affiliated (Tumour) Hospital, Harbin Medical University, Harbin, China.
authors.forename: Cong
authors.initials: C
authors.lastname: Li
authors.forename: Yinghong
authors.initials: Y
authors.lastname: Li
authors.forename: Xiaochuan
authors.initials: X
authors.lastname: Wang
authors.forename: Zhenyu
authors.initials: Z
authors.lastname: Wang
authors.forename: Jianping
authors.initials: J
authors.lastname: Cai
authors.forename: Lihua
authors.initials: L
authors.lastname: Wang
authors.forename: Yulan
authors.initials: Y
authors.lastname: Zhao
authors.forename: Hongtao
authors.initials: H
authors.lastname: Song
authors.forename: Xiangning
authors.initials: X
authors.lastname: Meng
authors.forename: Xiaoming
authors.initials: X
authors.lastname: Ning
authors.forename: Chunlin
authors.initials: C
authors.lastname: Xu
authors.forename: Mei
authors.initials: M
authors.lastname: Lin
authors.forename: Lejing
authors.initials: L
authors.lastname: Li
authors.forename: Jingshu
authors.initials: J
authors.lastname: Geng
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015815:Cell Adhesion Molecules / Q000235:genetics* / Q000378:metabolism; D002681:China / Q000453:epidemiology; D002945:Cisplatin / Q000494:pharmacology / Q000627:therapeutic use*; D018284:Cystadenocarcinoma, Serous / Q000175:diagnosis* / Q000235:genetics / Q000401:mortality; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006801:Humans; D008565:Membrane Proteins; D008875:Middle Aged; D009367:Neoplasm Staging; D018365:Neoplasm, Residual; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000401:mortality; D016601:RNA-Binding Proteins; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D015815:Cell Adhesion Molecules; C483039:MTDH protein, human; D008565:Membrane Proteins; D016601:RNA-Binding Proteins; D002945:Cisplatin